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Abstract  
Growing evidence points to the role of epigenetic mechanisms, including DNA methylation, in 
substance use and addiction. We conducted a systematic review of 47 recent (2012-15) animal and 
human studies that investigate DNA methylation and substance use/exposure, spanning 
preconception to adulthood. The majority of extant studies (i) focused on exposure during 
adulthood, (ii) examined the effects of alcohol use, (iii) employed a candidate gene approach and 
(iv) were cross-sectional. While studies generally support an association between substance 
use/exposure and DNA methylation, and also suggest that developmental context and timing matter, 
dearth of longitudinal data and low comparability across studies currently limits the conclusions 
that can be drawn. Future challenges and directions for the field are discussed.  
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Introduction  
Addiction to psychoactive substances (e.g. alcohol, illicit drugs) is a debilitating condition 
characterized by compulsive drug-seeking and repeated harmful use, despite adverse consequences 
[1]. Like other complex diseases, addiction results from both genetic and environmental factors, 
which combine to exert additive, evocative and interactive effects across the lifespan [2]. How such 
gene-environment associations operate at a molecular level, however, remains unclear. In recent 
years, epigenetic mechanisms have been proposed as a potential candidate, as they respond to both 
genetic and environmental influences [3, 4] and are thought to mediate vulnerability to disorders, 
including addiction [3, 4]. 
Epigenetic mechanisms, such as DNA methylation (DNAm) regulate when and where genes are 
expressed without changing the DNA sequence itself [5]. DNAm refers to the addition of a methyl 
group, primarily in the context of cytosine-guanine (CpG) dinucleotides. The genome contains in 
excess of 28 million CpG sites, around 10% of which cluster into CpG ‘islands’, close to gene 
promoter regions [6].  Methylated CpG islands impede transcription factors from accessing the 
DNA sequence. As such, DNAm is typically associated with decreased gene expression, although 
the functional role of methylation changes within genomic regions other than CpG islands (e.g. 
intergenic regions) remains unclear [7]. Importantly, DNAm is dynamic across the lifespan – 
although patterns are mitotically stable, which can lead to long-term alterations in gene activity, 
they also show a considerable degree of flexibility over time, enabling cells to respond to changing 
internal and external inputs [8]. 
A growing number of studies have begun to clarify the role of DNAm in substance abuse and 
addiction. Experimental studies in animals have led the way, documenting a number of important 
findings. First, substance use can alter DNAm – for example, repeated administration of substances 
(e.g. alcohol, cocaine) has been found to modify methylation patterns in the reward regions of the 
brain (e.g. striatum [9]). Second, DNAm contributes to the pathophysiology of addiction. 
Specifically, drug-induced methylation changes have been shown to influence the expression of 
genes involved in synaptic plasticity and memory consolidation, which in turn drive long-term 
neuroadaptations underlying the onset and persistence of addictive behaviours [4]. Third, animal 
studies have begun to shed light on the role of developmental context on DNAm and addiction risk. 
For example, alcohol intake during the first half of pregnancy has been found to alter epigenetic 
patterns in the developing embryo, leading to reduced fetal growth and congenital abnormalities 
similar to those observed in human fetal alcohol syndrome, as well as subsequent risk for addiction 
[10].     
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So far, studies in humans have provided initial support for animal findings, reporting methylomic 
differences between substance abusers and drug-free controls across a number of substances and 
tissue types [11, 9]. However, unlike animal studies that make it possible to experimentally 
manipulate the type, extent and timing of substance exposure, studies in humans have been 
primarily cross-sectional and correlational, making the causal links between epigenetic changes and 
subsequent addiction more problematic to draw.  
The aim of this systematic review is three-fold: (i) to collate findings from recent animal and human 
research investigating the link between substance exposure, DNAm and addiction; (ii) to consider 
the relevance of timing of substance exposure, beginning in preconception through to adulthood; 
and (iii) to outline future directions for the field.  
 
Methods  
Inclusion criteria 
We included studies that investigated associations between DNAm and substance use/exposure. In 
line with the journal’s focus on current research, we only included articles published during the past 
three years (01-01-2012 to 31-02-2015). No restriction was applied regarding: (i) species (e.g. 
human, mouse), (ii) period of exposure (e.g. prenatal, adulthood), (iii) substance (e.g. alcohol, 
cocaine), (iv) tissue (e.g. blood, brain), (v) approach (e.g. candidate vs genome-wide), and (vi) 
design (e.g. cross-sectional vs longitudinal).  
Search strategy 
PubMed and PsychInfo were searched for relevant studies written in English. Search terms were 
applied in MeSH or index terms, as well as text words. Included terms related to either (i) DNA 
methylation (e.g. methylat*; epigen*), or (ii) substance (e.g. substance use, abuse, dependence; 
drug; addiction; cocaine; heroin; cannabis; alcohol; opiate*; smoking; tobacco). ‘Cancer’ and 
‘medication’ were specified as exclusion terms to avoid studies investigating DNAm in relation to 
clinical drugs.  
Study selection 
Our search yielded 621 records, with 381 remaining after filtering out duplicates (see Figure 1). 
Titles and abstracts were screened and studies excluded if they were not empirical (e.g. reviews), 
focussed on epigenetic mechanisms other than DNAm (e.g. histone modifications) or examined 
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drugs other than the ones specified above (e.g. clinical drugs).  Given that the majority of DNAm 
studies on tobacco use examined medical diseases (e.g. cancer) as opposed to addiction-relevant 
phenotypes, studies with tobacco were not included in the review. 61 studies were retained and their 
full-text articles were assessed for eligibility. 16 articles were removed due to the following 
reasons: (i) 6 did not include DNAm data; (ii) 6 did not report direct associations between DNAm 
and substance use/exposure; (iii) 2 did not include substance data; (iv) 1 was published before 2012;  
and (v) 1 was based on cell culture data. A total of 45 original reports were included in the 
systematic review. 
 
Results  
Descriptive summary 
Study characteristics are summarized in Table 1 (see also Figure 2). 24 the studies examined 
animal samples (nrat = 14 and nmouse = 10) and 21 examined humans. The majority of studies 
investigated substance exposure during adulthood (n = 33), focused on alcohol (n = 36), involved 
peripheral samples (n = 25), examined DNAm at a single time point (n = 40) and used a candidate 
gene approach (n = 26). The most common peripheral tissue examined was blood (n = 18), followed 
by liver, sperm, pancreas, saliva, placenta, kidney, intestine and colon. Most commonly examined 
central tissues were prefrontal cortex (n = 5) and hippocampus (n = 4), followed by nucleus 
accumbens, hypothalamus, amygdala, cerebellum, ventral tegmental area, striatum and neocortex. 
Below, we describe findings first in animals and then in humans, in order of developmental period 
of substance exposure.  
Animal studies  
Preconception  
Three candidate gene studies investigated parental alcohol use prior to conception. In the first, 
paternal consumption in mice related to decreased DNAm of Bdnf – implicated in stress response 
and neural development – in paternal sperm cells and offspring ventral tegmental area [12]. In the 
second, paternal alcohol consumption in rats was associated with increased Pomc methylation – 
another gene relevant in stress response –in both parental sperm and offspring hypothalamus, 
although findings were specific to the male germline [13]. In contrast, the third study [14] found 
that DNAm in H19 CTCF binding sites - involved in imprinting mechanisms - was reduced in 
offspring tail blood but not paternal sperm cells.  
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Prenatal 
Three studies from the same working group found that prenatal alcohol exposure associated with 
increased Pomc methylation in the rat hypothalamus, which in turn related to decreased gene 
expression [15, 16, 13]. These changes were maintained transgenerationally (up to three 
generations), but could be rescued by gestational choline supplementation. Epigenome-wide 
associations between prenatal alcohol exposure and DNAm in brain tissue from adult offspring 
were identified by one study, particularly within genetic pathways related to nervous system 
development (including the Cdk5 signaling pathway) and neurological diseases, including the 
Alzheimer disease-linked gene App [17]. Another study found that in utero exposure to 
methamphetamine was associated with aberrant hippocampal DNAm in adolescent mice offspring 
[18]. Hypermethylated genetic pathways related to cerebral cortex GABAergic interneuron 
differentiation, while hypomethylated pathways related to embryonic development. 
Neonatal 
Two mouse studies investigated the effect of neonatal alcohol exposure on global methylation 
within the hippocampus and neocortex [19, 20]. While the first study reported a reduction in global 
methylation in response to acute alcohol exposure (8 and 24 hours post-exposure; [20]), the second 
study observed an increase in global methylation in the exposed group across both regions, which 
could be partially ameliorated by choline treatment [21]. Although of interest, it is important to note 
that neonatal substance exposure may be less relevant to human studies compared to other 
developmental periods, as it is relatively uncommon in humans.  
Adulthood 
This developmental period received by far the greatest research attention (71% of animal studies, n 
= 17) and was primarily examined in relation to alcohol exposure (n = 11). In global methylation 
studies, exposed mice were found to have lower DNAm in the cerebral cortex [21] but not in liver 
[22], although reductions were reported in global DNA hydroxymethylation (another type of DNA 
modification, characterized by the addition of a hydroxymethyl group). Findings from candidate 
gene studies further indicated that alcohol exposure in adulthood is associated with increased 
DNAm in multiple genes, including the serotonin receptor Htr3a in blood and hippocampal tissue 
[23], the sodium transporter Slc5a6 gene in pancreatic tissue [24] and immune-function TLR-
pathway genes in the liver [25]. Decreased DNAm was instead observed for the glutamate gene 
Nr2b in the prefrontal cortex [26] and Bdnf gene in motile sperm [12]. Tissue- and gene-specific 
DNAm alterations were identified by one study in folate-regulating genes [27]. Finally, no 
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associations were found in opioid-related genes Pdny and Pnoc in the rat amygdala [28], as well as 
imprinting-control genes H19 and Rasgfl in mouse sperm [14].  
Seven studies examined DNAm in relation to cocaine and/or opiate exposure. No associations with 
global methylation were reported in the corpus callosum of cocaine-exposed rats after 1 or 30 days 
of forced abstinence [29], as well as cocaine or heroin-exposed mice [30] – although a specific 
reduction in hydroxymethylation in the liver following cocaine administration was reported within 
the same sample [31]. Drug- and tissue-specific effects were also identified in [32], where global 
DNAm reductions were evident in the prefrontal cortex (but not nucleus accumbens) of mice 
exposed to cocaine (not heroin) – an effect that was reversible through repeated administration of 
methionine. With regards to candidate genes, increased Drd2 receptor methylation was observed in 
the nucleus accumbens of rats exposed to glucocorticoids in utero [33]. This association was 
specific to morphine administration and reversed by L-dopa treatment. Also in the nucleus 
accumbens, repeated SAM pre-treatment was found to modify cocaine-induced methylation 
changes in the neuropeptides Cck and Gal  as well as the glutamate transporter Slc17a7 [34]. Pol 
Bodetto et al [35] reported that methylation of Pp2cβ, a gene involved in cellular function, was 
higher in the brain of cocaine-exposed rats vs controls. Finally, in a study investigating myelin-
producing genes, reduced mean DNAm of Sox10 was identified in the corpus callosum of cocaine-
exposed rats, particularly after a period of forced abstinence [29]. None of the studies examined 
epigenome-wide alterations in response to adult substance exposure.  
 
Human studies 
Prenatal 
Two studies examined DNAm in relation to prenatal alcohol exposure. Wilhelm-Benartzi et al. [36] 
found that maternal alcohol intake positively associated with global LINE-1 (but not AluYb8) 
methylation in placental tissue. One candidate gene study found that cord blood methylation of the 
developmental gene ZAC1 positively correlated with prenatal maternal alcohol intake as well as 
associating with reduced fetal and postnatal weight [37].  
Adolescence 
Only one study examined adolescent substance use. Researching the impact of cannabis smoking on 
whole blood COMT methylation (important for neurotransmitter catalysis), van der Knaap et al [38] 
found no main effect of cannabis use. However, a significant methylation by genotype interaction 
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was identified, where Met/Met carriers with higher DNAm were least likely to be frequent cannabis 
users.  
Adulthood 
85% of studies in humans (n = 18) examined adult substance use, again focusing primarily on 
alcohol exposure (n = 16). One global methylation study found decreased DNAm in the blood of 
alcohol drinkers (Alu, not LINE-1 [39]). Results contrast those of increased global methylation 
identified in the frontal cortex of HIV+ methamphetamine users vs non users [40] as well as in the 
blood of methadone-substituted former opiate addicts, an effect which was also replicated in 
independent sample of opioid-treated patients [41].  
Candidate gene studies focused mainly on genes involved in neural function, most likely guided by 
existing neurochemical data regarding addiction on animals and humans. Higher DNAm was 
observed in the blood of alcohol-dependent individuals within the HTR3A serotonin receptor gene 
[42] and OPRM1 opioid receptor gene [43] – an association that was also identified in opiate 
addicts [41]. Lower DNAm of the leptin hormone (LEP) gene was instead identified in the blood of 
patients with stronger alcohol cravings [44]. No significant associations were reported between 
alcohol use and DNAm in a number of genes, including PDNY and PNOC opioid-related genes 
(blood; [42]), the serotonin transporter 5-HTT in females exposed to trauma (alcohol, cannabis; 
[45]), the DAT dopamine transporter in blood [46] and the drug metabolism gene UGT1A1 in 
human liver [47]. Of the candidate gene studies reviewed, two featured repeated measures of 
DNAm, comparing alcohol-dependent cases vs controls at baseline, day 7 and day 14 post-
treatment admission. While the first found significant differences in DNAm of volume-regulating 
neuropeptides AVP and ANP both at baseline and between day 7 and 14 of withdrawal [48], the 
second [49] reported increased nerve growth factor (NGF) methylation in cases vs controls, but 
only between day 7 and 14.  
All epigenome-wide investigations focussed on the effect of alcohol in blood. Generally, results 
were mixed, depending on sample characteristics and methods. In terms of specific genes, two 
EWAS studies confirmed associations with alcohol metabolism-related genes, including alcohol 
and aldehyde dehydrogenases (ADH1A, ADH7, ALDH3B2, ALDH1A2) and cytochrome P450 2A13 
[50, 51]. In one study [52], the tumor suppressor gene BLCAP and ABR – involved in vestibular 
morphogenesis – were hypomethylated in heavy alcohol drinkers vs abstinent controls, suggesting 
one mechanism by which tumor risk may be higher in alcohol drinkers. In another study, alcohol-
dependent discordant siblings showed hypomethylation of SSTR4 – an important gene for hormonal 
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function – and hypermethylation of the GABA receptor gene GABRP [53].  Finally, two EWAS 
studies measured DNAm at multiple time points: before and after a 25-day treatment program [54], 
or a 12-year interim period [55]. While the former [54] found no significant differences pre-vs-post 
treatment, the latter [55] observed a general increase in methylation with alcohol consumption over 
a 12-year period, particularly in CKM, PHOX2A and NPDC1. With regards to wider biological 
pathways, EWAS studies indicated that the most common pathways that were hypermethylated in 
response to alcohol use were those related to G-protein mediated and GTPase signal transduction 
processes [55, 54, 51], whereas pathways associated with stimulus and stress responses, as well as 
immune and inflammatory processes, where likely to be hypomethylated [51]. Hypomethylation 
was also observed in long terminal repeat (LTR) regions of retrotransposons in the superior frontal 
cortex of post-mortem alcohol users [56]. Other important pathways related to apoptosis [55, 52, 
54], metabolism [53], as well as GABA and dopamine systems [53, 40].  
 
Discussion  
The aim of the present review was to summarize the latest animal and human research investigating 
the association between substance use, DNA methylation and addiction risk, spanning 
preconception to adulthood. Based on the 45 reports included, we may conclude that there is 
preliminary support for a link between substance exposure, DNAm and addiction. However, 
findings are often mixed and have limited comparability. In this section, we review key similarities 
and differences across studies, evaluate evidence for the importance of timing of substance 
exposure and outline future directions for the field.  
Summary of study characteristics and findings 
The majority of studies across species focused on substance exposure during adulthood, examined 
the effects of alcohol, employed a candidate gene approach and were cross-sectional. One key 
difference related to tissue, with animal studies most often investigating brain samples and human 
studies examining DNAm in blood. Global methylation studies were more common in rodents, 
while epigenome-wide studies were more frequently carried out in humans. Although prospective 
longitudinal designs were more common in animal studies, the only four reports to include repeated 
DNAm measures were based on humans.  
As a symptom of how young the field is, there are not sufficient data to assess how DNAm of 
specific genes relates to exposure to specific substances across developmental periods and tissue 
types. We do, however, highlight five genes that were investigated by multiple studies and, 
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promisingly, showed a consistent direction of associations. In three rodent studies from the same 
working group [15, 16, 13], increased methylation and decreased expression of Pomc – a gene 
implicated in stress response, metabolism and immune function – was observed in response to 
prenatal alcohol exposure across multiple tissues. These results highlight one mechanism through 
which fetal alcohol programming can occur, contributing to HPA axis dysregulation and increased 
addiction risk [16]. In two other studies, the opioid receptor mu 1 (OPRM1) – a gene important for 
mediating drug-induced activation of reward pathways – was hypermethylated in the blood of 
former opiate addicts [41] and alcohol-dependent individuals [43]. It was not possible to establish, 
however, whether higher methylation was a predisposing factor for addiction and/or a consequence 
of long-term substance use.  Furthermore, hypermethylation of the serotonin receptor 3A (HTR3A) 
was identified in relation to alcohol exposure across both humans [42] and rodents [23]. Finally, a 
null association between alcohol exposure and methylation in the opioid signaling genes PDNY and 
PNOC was reported in human blood [42] and brain tissue in rats [28]. Despite these consistent 
findings, It is noteworthy that genes investigated by candidate studies did not typically converge 
with those identified by studies using hypothesis-free, epigenome-wide analyses. Instead, EWAS 
studies more often reported significant associations with drug metabolizing genes, as well as 
highlighting wider biological pathways linked to substance exposure, including signal transduction, 
inflammation, and apoptosis, in addition to stress response and neurotransmission. How these 
pathways specifically contribute to addiction, however, remains unclear. 
Given the limited comparability across studies, we were not able to systematically assess the 
importance of developmental context in the relationship between substance use, DNAm and 
addiction risk. However, the studies reviewed did provide preliminary support for the relevance of 
timing of substance exposure on DNAm. For example, evidence from animal models demonstrated 
that substance exposure can influence DNAm even prior to conception, supporting the existence of 
transgenerational effects [12-14]. Studies also pointed to the prenatal period as a particularly 
sensitive developmental window. For example, in utero substance exposure influenced DNAm of 
developmental genes, which in turn affected postnatal outcomes (e.g. reduced postnatal weight 
[37]), although the relevance of these changes for addiction risk is yet to be characterized. It is 
important to note that the period between birth and adulthood received very little attention. In fact, 
none of the studies investigated childhood and only one examined adolescence – a key period of 
vulnerability for the development of substance use disorders [57]. 
 
 
DNA methylation, substance use and addiction 
11 
 
Current challenges for the field 
Despite considerable advances in epigenetic research, studies investigating the role of DNAm in 
substance use and addiction continue to face a number of key challenges [58, 11]. Firstly, our 
knowledge of the methylome is still limited. Because we know little about ‘typical’ methylation 
patterns in humans, it is difficult to establish when such patterns deviate to contribute to diseased 
states. This is complicated by the fact that DNAm patterns can vary across multiple factors, 
including tissue, cell-type, sex and age [59]. In general, the compilation of reference datasets will be 
important for providing a ‘typical’ benchmark against which to compare epigenetic findings.  
Knowledge is also limited regarding the relative contribution of genetic and environmental 
influences on observed methylation patterns, which will require the use of genetically-informative 
designs, such as twin studies and studies identifying methylation quantitative trait loci [60, 61]. 
More work will also be needed to determine the functional significance of identified DNAm 
changes at transcriptomic, metabolomic, proteomic and neural biological levels.  
A second set of challenges relates to research methodology. Methods have varied widely across 
studies, including differences in pre-processing, quality control, genomic coverage, data analysis, 
choice of covariates and significance thresholds used for detecting effects. Together, these sources 
of variability have limited comparability across studies and complicated efforts to replicate findings 
– a necessary step for weeding out false-positives. The increased availability of standardized 
pipelines will considerably help in this respect [62]. Furthermore, the integration of discovery and 
replicate samples will become increasingly important, as was the case for genomic studies. More 
research will also be needed to determine what sample sizes are required to reach appropriate 
statistical power, although simulation-based studies are beginning to provide recommendations 
[63].  
A third issue relates to difficulties in establishing causal relationships between substance use, 
DNAm and addiction. Most of the studies reviewed adopted a cross-sectional approach with DNAm 
data sampled at only one time point. Human studies, in particular, focussed primarily on adults who 
had already been exposed to substances. As such, it remains unclear whether DNAm can be a risk 
factor for, as well as a consequence of substance use, and how substance exposure and DNAm 
interrelate over time to influence addiction risk.  
Below, we propose a number of ways in which future research may strengthen causal inferences 
and improve understanding of the role of DNAm in substance exposure and addiction.  
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A proposed model for conducting research on DNA methylation, substance use and addiction 
Firstly, it will be important to capitalize on the strengths of animal models to clearly delineate the 
mechanisms linking substance exposure, DNAm and addiction. Systematic investigations will need 
to be conducted within a given substance, across multiple tissues, over developmental periods and 
in different strains. Importantly, it will be necessary to collect prospective, repeated measures of 
DNAm pre- and post- substance exposure, in order to (i) investigate whether pre-exposure DNAm 
predicts individual differences in drug-seeking behaviours, (ii) trace the timing and stability of 
DNAm changes following exposure, and (iii) clarify whether DNAm mediates the effect of 
substance use on the onset and persistence of addiction. The sampling of multiple tissues over time 
will also make it possible to establish cross-tissue variability and locate peripheral biomarkers that 
most closely resemble DNAm changes in neural networks underlying addiction. Furthermore, 
incorporating additional omics data, such as gene expression, serum levels, protein content and 
enzymatic activity, will be useful for clarifying the functional relevance of observed DNAm 
changes at multiple biological levels [e.g. 16, 13]. Importantly, the use of methyl-modifying agents 
(e.g. methionine, choline [15, 32]) will offer valuable opportunities for testing the reversibility of 
drug-induced DNAm changes, identifying whether certain developmental periods are more 
sensitive to intervention, and examining whether normalization of DNAm patterns parallel changes 
in addiction-relevant phenotypes. Finally, the availability of methylomic data in relation to different 
substances will enable to disentangle DNAm markers that are common to multiple substances 
(perhaps reflecting a general liability to addiction) as opposed to substance-specific markers.  
The knowledge generated from animal research could then be used to inform the design of human 
studies and to map out the most promising DNAm markers for further investigation. This will 
require, however, the use of strategies to maximise cross-species comparability. For example, the 
use of data from epidemiological birth cohorts that feature repeated measures of DNA [e.g. 64], 
could allow researchers to examine whether pre- vs post-exposure DNAm changes identified in 
longitudinal animal studies extend to humans. Furthermore, analytic methods that make it possible 
to integrate repeated measures of environmental exposure (e.g. substance use), DNAm and 
phenotypic outcomes (e.g. addiction) – such as structural equation modelling – will be particularly 
useful for tracing longitudinal associations and for testing mediation hypotheses [65]. The 
development of advanced causal inference methods, such as two-step epigenetic Mendelian 
Randomization [66,67], may also show promise for testing causal pathways documented in animals. 
As discussed above, the inclusion of additional biological markers (e.g. serum levels) will be 
necessary for establishing the functional relevance of identified DNAm markers. Furthermore, 
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given the scarce availability of central tissues in human research (i.e. post-mortem), it will be 
important in future to investigate whether peripheral DNAm markers can be related to in vivo 
structural and functional brain data (e.g. striatal activity when viewing addiction-related cues). 
Finally, increased use of approaches that capitalize on co-methylation patterns between CpG sites, 
such as regional or network-based approaches, will be important for reducing multiple testing and 
increasing power to detect effects in humans, enabling to move beyond individual methylation sites 
towards wider biological systems [68].  
Conclusions 
DNA methylation is emerging as an important molecular mechanism mediating substance use 
response and addiction risk. However, the limited understanding of the epigenome, heterogeneity 
across studies, a reliance on cross-sectional designs and lack of replications make it difficult to 
interpret the relevance of the extant data for mechanisms of addiction. Rapid developments in 
knowledge, methodology and research designs will offer exciting opportunities for delineating the 
role of DNAm in the pathophysiology of addiction, as well as testing its potential clinical utility as 
an exposure indicator, disease biomarker and therapeutic target.  
 
 
 
 
 
 
 
 
 
 
 
 
DNA methylation, substance use and addiction 
14 
 
References  
1. McQuown SC, Wood MA. Epigenetic regulation in substance use disorders. Current psychiatry 
reports. 2010;12(2):145-53. doi:10.1007/s11920-010-0099-5. 
2. Kendler KS, Chen X, Dick D, Maes H, Gillespie N, Neale MC et al. Recent advances in the 
genetic epidemiology and molecular genetics of substance use disorders. Nature neuroscience. 
2012;15(2):181-9. doi:10.1038/nn.3018. 
3. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. 
Nature reviews Neuroscience. 2007;8(5):355-67. doi:10.1038/nrn2132. 
4. Nestler EJ. Epigenetic mechanisms of drug addiction. Neuropharmacology. 2014;76 Pt B:259-68. 
doi:10.1016/j.neuropharm.2013.04.004. 
5. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates 
intrinsic and environmental signals. Nature genetics. 2003;33 Suppl:245-54. 
doi:10.1038/ng1089. 
6. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M et al. DNA methylation 
profiling of human chromosomes 6, 20 and 22. Nature genetics. 2006;38(12):1378-85. 
doi:10.1038/ng1909. 
7. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature 
reviews Genetics. 2012;13(7):484-92. doi:10.1038/nrg3230. 
8. Alabert C, Groth A. Chromatin replication and epigenome maintenance. Nature reviews 
Molecular cell biology. 2012;13(3):153-67. doi:10.1038/nrm3288. 
9. Wong CC, Mill J, Fernandes C. Drugs and addiction: an introduction to epigenetics. Addiction 
(Abingdon, England). 2011;106(3):480-9. doi:10.1111/j.1360-0443.2010.03321.x. 
10. Kaminen-Ahola N, Ahola A, Maga M, Mallitt KA, Fahey P, Cox TC et al. Maternal ethanol 
consumption alters the epigenotype and the phenotype of offspring in a mouse model. PLoS 
Genet. 2010;6(1):e1000811. doi:10.1371/journal.pgen.1000811. 
11. Harlaar N, Hutchison KE. Alcohol and the methylome: design and analysis considerations for 
research using human samples. Drug and alcohol dependence. 2013;133(2):305-16. 
doi:10.1016/j.drugalcdep.2013.07.026. 
12. Finegersh A, Homanics GE. Paternal alcohol exposure reduces alcohol drinking and increases 
behavioral sensitivity to alcohol selectively in male offspring. PloS one. 2014;9(6):e99078. 
doi:10.1371/journal.pone.0099078. 
DNA methylation, substance use and addiction 
15 
 
13. Govorko D, Bekdash RA, Zhang C, Sarkar DK. Male germline transmits fetal alcohol adverse 
effect on hypothalamic proopiomelanocortin gene across generations. Biol Psychiatry. 
2012;72(5):378-88. doi:10.1016/j.biopsych.2012.04.006. 
14. Knezovich JG, Ramsay M. The effect of preconception paternal alcohol exposure on epigenetic 
remodeling of the h19 and rasgrf1 imprinting control regions in mouse offspring. Frontiers in 
genetics. 2012;3:10. doi:10.3389/fgene.2012.00010. 
15. Bekdash RA, Zhang C, Sarkar DK. Gestational choline supplementation normalized fetal 
alcohol-induced alterations in histone modifications, DNA methylation, and 
proopiomelanocortin (POMC) gene expression in beta-endorphin-producing POMC neurons of 
the hypothalamus. Alcoholism, clinical and experimental research. 2013;37(7):1133-42. 
doi:10.1111/acer.12082. 
16. Gangisetty O, Bekdash R, Maglakelidze G, Sarkar DK. Fetal alcohol exposure alters 
proopiomelanocortin gene expression and hypothalamic-pituitary-adrenal axis function via 
increasing MeCP2 expression in the hypothalamus. PloS one. 2014;9(11):e113228. 
doi:10.1371/journal.pone.0113228. 
17. Laufer BI, Mantha K, Kleiber ML, Diehl EJ, Addison SM, Singh SM. Long-lasting alterations 
to DNA methylation and ncRNAs could underlie the effects of fetal alcohol exposure in mice. 
Disease models & mechanisms. 2013;6(4):977-92. doi:10.1242/dmm.010975. 
18. Itzhak Y, Ergui I, Young JI. Long-term parental methamphetamine exposure of mice influences 
behavior and hippocampal DNA methylation of the offspring. Molecular psychiatry. 
2015;20(2):232-9. doi:10.1038/mp.2014.7. 
19. Nagre NN, Subbanna S, Shivakumar M, Psychoyos D, Basavarajappa BS. CB1-receptor 
knockout neonatal mice are protected against ethanol-induced impairments of DNMT1, 
DNMT3A, and DNA methylation. Journal of neurochemistry. 2015;132(4):429-42. 
doi:10.1111/jnc.13006. 
20. Otero NK, Thomas JD, Saski CA, Xia X, Kelly SJ. Choline supplementation and DNA 
methylation in the hippocampus and prefrontal cortex of rats exposed to alcohol during 
development. Alcoholism, clinical and experimental research. 2012;36(10):1701-9. 
doi:10.1111/j.1530-0277.2012.01784.x. 
21. Fowler AK, Hewetson A, Agrawal RG, Dagda M, Dagda R, Moaddel R et al. Alcohol-induced 
one-carbon metabolism impairment promotes dysfunction of DNA base excision repair in adult 
brain. The Journal of biological chemistry. 2012;287(52):43533-42. 
doi:10.1074/jbc.M112.401497. 
DNA methylation, substance use and addiction 
16 
 
22. Tammen SA, Dolnikowski GG, Ausman LM, Liu Z, Sauer J, Friso S et al. Aging and alcohol 
interact to alter hepatic DNA hydroxymethylation. Alcoholism, clinical and experimental 
research. 2014;38(8):2178-85. doi:10.1111/acer.12477. 
23. Barker JM, Zhang Y, Wang F, Taylor JR, Zhang H. Ethanol-induced Htr3a promoter 
methylation changes in mouse blood and brain. Alcoholism, clinical and experimental research. 
2013;37 Suppl 1:E101-7. doi:10.1111/j.1530-0277.2012.01906.x. 
24. Srinivasan P, Kapadia R, Biswas A, Said HM. Chronic alcohol exposure inhibits biotin uptake 
by pancreatic acinar cells: possible involvement of epigenetic mechanisms. American journal of 
physiology Gastrointestinal and liver physiology. 2014;307(9):G941-9. 
doi:10.1152/ajpgi.00278.2014. 
25. Khachatoorian R, Dawson D, Maloney EM, Wang J, French BA, French SW et al. SAMe 
treatment prevents the ethanol-induced epigenetic alterations of genes in the Toll-like receptor 
pathway. Experimental and molecular pathology. 2013;94(1):243-6. 
doi:10.1016/j.yexmp.2012.09.024. 
26. Qiang M, Li JG, Denny AD, Yao JM, Lieu M, Zhang K et al. Epigenetic mechanisms are 
involved in the regulation of ethanol consumption in mice. Int J Neuropsychopharmacol. 
2014;18(2). doi:10.1093/ijnp/pyu072. 
27. Wani NA, Hamid A, Kaur J. Alcohol-associated folate disturbances result in altered methylation 
of folate-regulating genes. Molecular and cellular biochemistry. 2012;363(1-2):157-66. 
doi:10.1007/s11010-011-1168-8. 
28. D'Addario C, Caputi FF, Ekstrom TJ, Di Benedetto M, Maccarrone M, Romualdi P et al. 
Ethanol induces epigenetic modulation of prodynorphin and pronociceptin gene expression in the 
rat amygdala complex. Journal of molecular neuroscience : MN. 2013;49(2):312-9. 
doi:10.1007/s12031-012-9829-y. 
29. Nielsen DA, Huang W, Hamon SC, Maili L, Witkin BM, Fox RG et al. Forced Abstinence from 
Cocaine Self-Administration is Associated with DNA Methylation Changes in Myelin Genes in 
the Corpus Callosum: a Preliminary Study. Frontiers in psychiatry. 2012;3:60. 
doi:10.3389/fpsyt.2012.00060. 
30. Fragou D, Zanos P, Kouidou S, Njau S, Kitchen I, Bailey A et al. Effect of chronic heroin and 
cocaine administration on global DNA methylation in brain and liver. Toxicology letters. 
2013;218(3):260-5. doi:10.1016/j.toxlet.2013.01.022. 
31. Chao MR, Fragou D, Zanos P, Hu CW, Bailey A, Kouidou S et al. Epigenetically modified 
nucleotides in chronic heroin and cocaine treated mice. Toxicology letters. 2014;229(3):451-7. 
doi:10.1016/j.toxlet.2014.07.023. 
DNA methylation, substance use and addiction 
17 
 
32. Tian W, Zhao M, Li M, Song T, Zhang M, Quan L et al. Reversal of cocaine-conditioned place 
preference through methyl supplementation in mice: altering global DNA methylation in the 
prefrontal cortex. PloS one. 2012;7(3):e33435. doi:10.1371/journal.pone.0033435. 
33. Rodrigues AJ, Leao P, Pego JM, Cardona D, Carvalho MM, Oliveira M et al. Mechanisms of 
initiation and reversal of drug-seeking behavior induced by prenatal exposure to glucocorticoids. 
Molecular psychiatry. 2012;17(12):1295-305. doi:10.1038/mp.2011.126. 
34. Anier K, Malinovskaja K, Pruus K, Aonurm-Helm A, Zharkovsky A, Kalda A. Maternal 
separation is associated with DNA methylation and behavioural changes in adult rats. European 
neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 
2014;24(3):459-68. doi:10.1016/j.euroneuro.2013.07.012. 
35. Pol Bodetto S, Carouge D, Fonteneau M, Dietrich JB, Zwiller J, Anglard P. Cocaine represses 
protein phosphatase-1Cbeta through DNA methylation and Methyl-CpG Binding Protein-2 
recruitment in adult rat brain. Neuropharmacology. 2013;73:31-40. 
doi:10.1016/j.neuropharm.2013.05.005. 
36. Wilhelm-Benartzi CS, Houseman EA, Maccani MA, Poage GM, Koestler DC, Langevin SM et 
al. In utero exposures, infant growth, and DNA methylation of repetitive elements and 
developmentally related genes in human placenta. Environmental health perspectives. 
2012;120(2):296-302. doi:10.1289/ehp.1103927. 
37. Azzi S, Sas TC, Koudou Y, Le Bouc Y, Souberbielle JC, Dargent-Molina P et al. Degree of 
methylation of ZAC1 (PLAGL1) is associated with prenatal and post-natal growth in healthy 
infants of the EDEN mother child cohort. Epigenetics : official journal of the DNA Methylation 
Society. 2014;9(3):338-45. doi:10.4161/epi.27387. 
38. van der Knaap LJ, Schaefer JM, Franken IH, Verhulst FC, van Oort FV, Riese H. Catechol-O-
methyltransferase gene methylation and substance use in adolescents: the TRAILS study. Genes, 
brain, and behavior. 2014;13(7):618-25. doi:10.1111/gbb.12147. 
39. Zhu ZZ, Hou L, Bollati V, Tarantini L, Marinelli B, Cantone L et al. Predictors of global 
methylation levels in blood DNA of healthy subjects: a combined analysis. International journal 
of epidemiology. 2012;41(1):126-39. doi:10.1093/ije/dyq154. 
40. Desplats P, Dumaop W, Cronin P, Gianella S, Woods S, Letendre S et al. Epigenetic alterations 
in the brain associated with HIV-1 infection and methamphetamine dependence. PloS one. 
2014;9(7):e102555. doi:10.1371/journal.pone.0102555. 
41. Doehring A, Oertel BG, Sittl R, Lotsch J. Chronic opioid use is associated with increased DNA 
methylation correlating with increased clinical pain. Pain. 2013;154(1):15-23. 
doi:10.1016/j.pain.2012.06.011. 
DNA methylation, substance use and addiction 
18 
 
42. Zhang H, Herman AI, Kranzler HR, Anton RF, Zhao H, Zheng W et al. Array-based profiling of 
DNA methylation changes associated with alcohol dependence. Alcoholism, clinical and 
experimental research. 2013;37 Suppl 1:E108-15. doi:10.1111/j.1530-0277.2012.01928.x. 
43. Zhang H, Herman AI, Kranzler HR, Anton RF, Simen AA, Gelernter J. Hypermethylation of 
OPRM1 promoter region in European Americans with alcohol dependence. J Hum Genet. 
2012;57(10):670-5. doi:10.1038/jhg.2012.98. 
44. Hillemacher T, Weinland C, Lenz B, Kraus T, Heberlein A, Glahn A et al. DNA methylation of 
the LEP gene is associated with craving during alcohol withdrawal. Psychoneuroendocrinology. 
2015;51:371-7. doi:10.1016/j.psyneuen.2014.10.014. 
45. Beach SR, Brody GH, Lei MK, Gibbons FX, Gerrard M, Simons RL et al. Impact of child sex 
abuse on adult psychopathology: a genetically and epigenetically informed investigation. Journal 
of family psychology : JFP : journal of the Division of Family Psychology of the American 
Psychological Association (Division 43). 2013;27(1):3-11. doi:10.1037/a0031459. 
46. Nieratschker V, Grosshans M, Frank J, Strohmaier J, von der Goltz C, El-Maarri O et al. 
Epigenetic alteration of the dopamine transporter gene in alcohol-dependent patients is 
associated with age. Addiction biology. 2014;19(2):305-11. doi:10.1111/j.1369-
1600.2012.00459.x. 
47. Yasar U, Greenblatt DJ, Guillemette C, Court MH. Evidence for regulation of UDP-
glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in 
healthy human livers. The Journal of pharmacy and pharmacology. 2013;65(6):874-83. 
doi:10.1111/jphp.12053. 
48. Glahn A, Riera Knorrenschild R, Rhein M, Haschemi Nassab M, Groschl M, Heberlein A et al. 
Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of 
vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification 
treatment. European addiction research. 2014;20(3):143-50. doi:10.1159/000357473. 
49. Heberlein A, Muschler M, Frieling H, Behr M, Eberlein C, Wilhelm J et al. Epigenetic down 
regulation of nerve growth factor during alcohol withdrawal. Addiction biology. 2013;18(3):508-
10. doi:10.1111/j.1369-1600.2010.00307.x. 
50. Harlaar N, Bryan AD, Thayer RE, Karoly HC, Oien N, Hutchison KE. Methylation of a CpG 
site near the ALDH1A2 gene is associated with loss of control over drinking and related 
phenotypes. Alcoholism, clinical and experimental research. 2014;38(3):713-21. 
doi:10.1111/acer.12312. 
51. Zhang R, Miao Q, Wang C, Zhao R, Li W, Haile CN et al. Genome-wide DNA methylation 
analysis in alcohol dependence. Addiction biology. 2013;18(2):392-403. doi:10.1111/adb.12037. 
DNA methylation, substance use and addiction 
19 
 
52. Philibert RA, Plume JM, Gibbons FX, Brody GH, Beach SR. The impact of recent alcohol use 
on genome wide DNA methylation signatures. Frontiers in genetics. 2012;3:54. 
doi:10.3389/fgene.2012.00054. 
53. Zhao R, Zhang R, Li W, Liao Y, Tang J, Miao Q et al. Genome-wide DNA methylation patterns 
in discordant sib pairs with alcohol dependence. Asia-Pacific psychiatry : official journal of the 
Pacific Rim College of Psychiatrists. 2013;5(1):39-50. doi:10.1111/appy.12010. 
54. Philibert RA, Penaluna B, White T, Shires S, Gunter T, Liesveld J et al. A pilot examination of 
the genome-wide DNA methylation signatures of subjects entering and exiting short-term 
alcohol dependence treatment programs. Epigenetics : official journal of the DNA Methylation 
Society. 2014;9(9):1212-9. doi:10.4161/epi.32252. 
55. Weng JT, Wu LS, Lee CS, Hsu PW, Cheng AT. Integrative epigenetic profiling analysis 
identifies DNA methylation changes associated with chronic alcohol consumption. Computers in 
biology and medicine. 2014. doi:10.1016/j.compbiomed.2014.12.003. 
56. Ponomarev I, Wang S, Zhang L, Harris RA, Mayfield RD. Gene coexpression networks in 
human brain identify epigenetic modifications in alcohol dependence. The Journal of 
neuroscience : the official journal of the Society for Neuroscience. 2012;32(5):1884-97. 
doi:10.1523/jneurosci.3136-11.2012. 
57. Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for 
addiction. Pharmacology, biochemistry, and behavior. 2007;86(2):189-99. 
doi:10.1016/j.pbb.2006.12.001. 
58. Mill J, Heijmans BT. From promises to practical strategies in epigenetic epidemiology. Nature 
reviews Genetics. 2013;14(8):585-94. doi:10.1038/nrg3405. 
59. Liang L, Cookson WOC. Grasping nettles: cellular heterogeneity and other confounders in 
epigenome-wide association studies. Human Molecular Genetics. 2014;23(R1):R83-R8. 
doi:10.1093/hmg/ddu284. 
60. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, Degner JF et al. DNA methylation 
patterns associate with genetic and gene expression variation in HapMap cell lines. Genome 
biology. 2011;12(1):R10-R. doi:10.1186/gb-2011-12-1-r10. 
61. Bell JT, Saffery R. The value of twins in epigenetic epidemiology. International journal of 
epidemiology. 2012. doi:10.1093/ije/dyr179. 
62. Morris TJ, Beck S. Analysis pipelines and packages for Infinium HumanMethylation450 
BeadChip (450k) data. Methods (San Diego, Calif). 2015;72:3-8. 
doi:10.1016/j.ymeth.2014.08.011. 
DNA methylation, substance use and addiction 
20 
 
63. Tsai P-C, Bell JT. Power and sample size estimation for epigenome-wide association scans to 
detect differential DNA methylation. International journal of epidemiology. 2015. 
doi:10.1093/ije/dyv041. 
64. Relton CL, Gaunt T, McArdle W, Ho K, Duggirala A, Shihab H et al. Data Resource Profile: 
Accessible Resource for Integrated Epigenomic Studies (ARIES). International journal of 
epidemiology. 2015. doi:10.1093/ije/dyv072. 
65. Cecil CA, Lysenko LJ, Jaffee SR, Pingault JB, Smith RG, Relton CL et al. Environmental risk, 
Oxytocin Receptor Gene (OXTR) methylation and youth callous-unemotional traits: a 13-year 
longitudinal study. Molecular psychiatry. 2014;19(10):1071-7. doi:10.1038/mp.2014.95. 
66. Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for 
establishing the causal role of epigenetic processes in pathways to disease. International journal 
of epidemiology. 2012;41(1):161-76. doi:10.1093/ije/dyr233. 
67. Pingault JB, Cecil CAM, Murray J, Munafò MR, Viding E. Causal inference in 
psychopathology: A systematic review of Mendelian randomisation studies aiming to identify 
environmental risk factors for psychopathology. Psychopathology Review. In Press. 
68. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. 
BMC bioinformatics. 2008;9:559. doi:10.1186/1471-2105-9-559. 
 
 
 
 
 
 
 
 
 
 
 
 
DNA methylation, substance use and addiction 
21 
 
Figure legends 
Figure 1. PRISMA flowchart detailing the filtering steps undertaken to select studies 
Figure 2. Flowchart of study characteristics. N.B. The same study may fit into multiple categories. 
Grey-shaded boxes represent developmental periods that have not been investigated. For each level 
(1-5) boxes are shaded according to study frequency (e.g. the least frequently investigated tissue is 
represented by lighter shading, while the most commonly investigated tissue is represented by 
darker shading). Boxes marked with an asterisk indicate presence of longitudinal studies with 
repeated measures of DNA methylation (here, boxes indicate the number of longitudinal studies out 
of the total number of studies). Abbreviations: Meth = methamphetamine; C = central tissue (brain); 
P = peripheral tissue; Ca = candidate gene; Ew = epigenome-wide; Gl = global. 
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Figure 1. PRISMA flowchart detailing the filtering steps undertaken to select studies 
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Table 1. Summary of study characteristics 
Summary Table (N = 45) 
Developmental period  
 Preconception 3 
 Prenatal 6 
 Neonatal 3 
 Childhood 0 
 Adolescence 1 
 Adulthood 33 
   Time points (DNAm)  
 1 TP 40 
 2 TP 3 
 3 TP 2 
   Approach  
 Candidate gene/s 26 
 Global DNAm 12 
 EWAS 9 
   Species  
 Animal 24 
 Human 21 
   Tissue  
 Peripheral 25 
 Central 21 
   Substance  
 Alcohol 36 
 Cocaine 6 
 Cannabis 6 
 Opiates 3 
 Methamphetamine 2 
 
N.B. The total number of studies for each characteristic may exceed 45 due to the presence of 
studies fitting multiple domains. To clarify, global methylation studies examine proxy markers of 
‘global’ DNAm, using repetitive elements such as Alu and Line-1 (comprising of 11-17% of the 
genome). Candidate studies focus on DNAm in individual, preselected genes (typically one) based 
on a priori hypotheses, while epigenome-wide studies (EWAS) are hypothesis-free and investigate 
thousands of DNAm markers across the genome.  
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Figure 2. Flowchart of study characteristics
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Table 2. Summary of study findings  
 
 
 
  
Reference Species Period of 
substance 
exposure 
DNAm 
N time 
points  
Substance Tissue Approach Gene Sample Findings 
1 Knezovich & 
Ramsay 
(2012) 
Animal 
(mouse) 
Pre-conception 
(F2); Adulthood 
(F1)  
1 Alcohol Sperm (F1); 
tail blood (F2) 
Candidate  H19,Rasgf
l 
F1: Male mice, 8 alcohol-
treated vs 7 controls. F2: 
offspring from alcohol-treated  
(n = 17 ) vs  controls sires (n = 
29). 
No significant difference in sperm methylation between 
alcohol-treated sires vs controls. H19 CTCF binding 
sites were significantly hypomethylated in alcohol-sired 
offspring compared to controls, which in turn 
associated with age restricted growth retardation.  
2 Finegersh & 
Homanics 
(2014) 
Animal 
(mouse) 
Pre-conception 
(F2); Adulthood 
(F1)  
1 Alcohol Sperm (F1); 
VTA; PFC 
(F2) 
Candidate  Bdnf F1: Male mice, 25 exposed to 
ethanol vapour  vs 27 controls. 
F2: offspring from alcohol-
treated  (n = 123; 45% F) vs 
control sires (n = 104; 50% F). 
 Paternal ethanol exposure associates with decreased 
Bdnf promoter methylation in motile sperm as well as 
VTA of ethanol-sired male and female offspring.  
3 Govorko et 
al. (2012) 
Animal 
(rat) 
Preconception; 
prenatal 
1 Alcohol Hypothalamus 
(ARC, PVN);  
blood 
(mononuclear 
cells); sperm 
Candidate  Pomc Male and female rats prenatally 
(GD 7-21) exposed to either an 
alcohol-liquid diet, a control-
liquid diet or rat chow (n = 
8/group). Also include F2 and 
F3 generation (n = 6-10/group).  
Prenatal alcohol exposure associated with increased 
Pomc methylation in POMC neurons and sperm. 
Suppression of methylation normalized expression 
levels and function. Alcohol-induced methylation 
alterations in exposed F1 offspring transmitted to F2 
and F3 male (but not female) germline.   
4 Itzhak et al. 
(2015)  
Animal 
(mouse) 
Preconception; 
prenatal 
1 Meth Hippocampus EWAS  - 60 offspring of 
methamphetamine-exposed 
(pre- and postconception) and 
62 offspring of control mice. 
DNAm  collected for a subset 
of female mice (PD40–PD45). 
DNAm platform: MeDIP; 
Roche NimbleGen 385k. 
62 and 35 promoter regions, in which DNA 
methylation was elevated and reduced, respectively, in 
the F1 mice due to in utero methamphetamine 
exposure. Enriched pathways included 'cerebral cortex 
GABAergic interneuron differentiation' for 
hypermethylated sites and 'embryonic development' for 
hypomethylated sites. 
5 Bekdash et 
al. (2013) 
Animal 
(rat) 
Prenatal 1 Alcohol Hypothalamus 
(mediobasal) 
Candidate  Pomc Male rats prenatally (GD 7-21) 
exposed to an alcohol-liquid 
diet or a control diet, with or 
without choline (n = 5/group).  
Prenatal alcohol exposure associated with increased 
Pomc methylation and decreased expression in the 
hypothalamus. Gestational choline normalized alcohol-
induced effects on Pomc methylation, expression and 
stress-axis function.  
6 Gangisetty et 
al. (2014) 
Animal 
(rat) 
Prenatal 1 Alcohol  Hypothalamus Candidate  Pomc Male rats exposed to alcohol 
prenatally (GD 7-21) vs 
controls.  
Prenatal alcohol exposure associated with increased 
Pomc methylation and decreased expression in the 
hypothalamus.  
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7 Laufer et al. 
(2013) 
Animal 
(mouse) 
Prenatal; 
neonatal 
1 Alcohol Whole brain EWAS  - Adult male mice (PD70), 6 
alcohol-exposed (cases) and 6 
matched controls. 
6660 promoter regions differentially methylated. 
Enriched pathways related to cell death and nervous 
system development. Network analysis indicated that 
the ‘Behavior, Neurological Disease, and Psychological 
Disorders’ network was the most significantly affected 
network, with App identified as a hub gene.  
8 Nagre et al. 
(2015) 
Animal 
(mouse) 
Neonatal 1 Alcohol  Neocortex; 
hippocampus 
Global - Neonatal (PD7) mice treated 
with ethanol (n=10) or saline 
(n=10);gender-matched. 
Global DNA methylation was reduced after ethanol 
exposure (8 and 24 h) compared to saline treatment (0 
h) in the hippocampus and neocortex. 
9 Otero et al. 
(2012) 
Animal 
(rat) 
Neonatal 1 Alcohol Hippocampus;
PFC 
Global - 28 choline-treated (13 ethanol/7 
intubation control/8 non-treated 
control)+ 64 non-choline-
treated mice (16ET/8IC/8NC); 
age- and sex-matched. 
Ethanol treatment associated with hypermethylation in 
the prefrontal and hippocampal region and this was 
partially ameliorated by choline treatment. 
10 Fowler et al. 
(2012) 
Animal 
(mouse) 
Adulthood 1 Alcohol Cerebral 
cortex 
Global - 10-12 week old male mice.  Long term but not short term ethanol exposure leads to 
OCM impairment seen from a significant decrease in 
global DNA methylation in brain. 
11 D'Addario et 
al. (2013) 
Animal 
(rat) 
Adulthood 1 Alcohol Amygdala Candidate  Pdyn, 
Pnoc 
Male rats exposed to alcohol for 
either 1 day, 5 days or 5 days 
plus 1 withdrawal day.  Each 
group compared to respective 
water-administered controls (n 
= 7/group). 
No significant association between alcohol exposure 
and DNA methylation of opioid peptide genes Pdyn 
and Pnoc within the amygdala. However, alcohol 
exposure associated with alterations in specific histone 
marks.  
12 Qiang et al. 
(2014) 
Animal 
(mouse) 
Adulthood 1 Alcohol  PFC Candidate  Nr2b Male eight-week old mice 
exposed to ethanol vs controls 
(n = 8 per group). 
Chronic intermittent ethanol exposure associated with 
decreased Nr2b methylation (18 CpGs) and increased 
expression levels in cases s controls. 
13 Rodrigues et 
al. (2012) 
Animal 
(rat) 
Adulthood 1 Alcohol/opi
ate 
/morphine 
Nucleus 
accumbens 
Candidate  Drd2 Male rats exposed to 
glucocorticoids in utero vs 
controls. Within these groups, 
half exposed to repeated 
morphine administration in 
adulthood (4 per group; 16 
total). 
Repeated morphine exposure associated with increased 
methylation (and decreased expression) of Drd2 in rats 
exposed to glucocorticoids. Drd2 methylation and 
expression changes in response to morphine reversed 
by L-dopa treatment.  
14 Tammen et 
al. (2014) 
Animal 
(mouse) 
Adulthood 1 Alcohol  Liver Global - Eighteen 18-month-old male 
mice and twenty 4-month-old 
mice. 
No effect of alcohol consumption on global DNA 
methylation. Reduced hydroxymethylation observed 
relative to mice fed a control diet in young, but not  old 
mice. 
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15 Khachatooria
n et al. 
(2013) 
Animal 
(rat) 
Adulthood 1 Alcohol Liver Candidate  24  genes Male rats fed ethanol or control 
diet, with or without SAM 
supplement for 1 month (n = 
3/group). 
Compared to controls, ethanol-fed rats showed higher 
methylation across genes - this increase was non-
significant for each individual gene, but significant for 
average methylation across genes. SAM-treatment 
prevented ethanol-induced methylation changes.  
16 Wani et al. 
(2012) 
Animal 
(rat) 
Adulthood 1 Alcohol  Intestine; 
colon; kidney; 
pancreas; liver 
Candidate  Fpgc, 
Ggh, Pcft, 
Rft  
Male chronically exposed to 
ethanol for three months vs 
controls (n = 6/group).  
Chronic ethanol feeding associated with tissue- and 
gene-specific methylation alterations in  folate 
regulating and transporting genes.  
17 Srinivasan et 
al. (2014) 
Animal 
(mouse) 
Adulthood 1 Alcohol  Pancreas Candidate  Slc5a6  Adult transgenic mice carrying 
the full-length human SLC5A6 
promoter, alcohol-fed vs 
controls.   
Chronic alcohol feeding associated with increased 
Slc5a6 promoter methylation, negatively influencing 
pancreatic biotin uptake.  
18 Barker et al. 
(2013) 
Animal 
(mouse) 
Adulthood 1 Alcohol Blood; 9 brain 
regions  
Candidate  Htr3a 15 male ethanol-drinking mice 
vs 13 water-drinking controls. 
Ethanol-drinking was associated with Htr3a 
hypermethylation in blood and hippocampus, but 
hypomethylation in the dorsomedial and ventromedial 
PFC. No significant differences in methylation across 
the other 6 brain regions investigated.  
19 Tian et al. 
(2012) 
Animal 
(mouse) 
Adulthood 1 Cocaine/ 
morphine 
Nucleus 
Accumbens; 
PFC 
Global - Adult male mice (no sample 
size or age information 
specified). 
Cocaine but not morphine induced global DNA 
hypomethylation in the prefrontal cortex (but not in the 
nucleus accumbens), which was reversible through 
methionine. 
20 Nielsen et al. 
(2012) 
Animal 
(rat) 
Adulthood 1 Cocaine Corpus 
callosum 
Global; 
candidate 
Mbp,Plp1,
Sox10 
19 male rats: sham rats with 1 
(n = 3) or 30 days (n = 4) of 
forced abstinence; cocaine self-
administration rats with 1 (n = 
6) or 30 days (n = 6) of forced 
abstinence. 
No difference in global DNA methylation. Candidate 
genes: reduced mean methylation of Sox10 relative to 
controls, especially after 30-day abstinence compared 
to 1-day abstinence. No differences in Mpb or Plp1 
sites.  
21 Anier et al 
(2013) 
Animal 
(mouse) 
Adulthood 1 Cocaine Nucleus 
accumbens; 
cerebellum 
Candidate  Slc17a7, 
Cck and 
Gal 
Male mice (5-6 months old) 
randomly assigned to one of 
four conditions (n = 8 per 
group): (i) saline + saline, (ii) 
SAM + saline, (iii) saline + 
cocaine), or (iv) SAM + 
cocaine.  
Repeated SAM pre-treatment modifies cocaine-induced 
methylation changes in Slc17a7, Cck and Gal within 
the nucleus accumbens but not in the cerebellum.   
22 Pol Bodetto 
et al. (2013) 
Animal 
(rat) 
Adulthood 1 Cocaine Caudate 
putamen 
Candidate  Pp2cβ Male 8-9 week old rats injected 
repeatedly (1 time daily x 10 
days) with either cocaine or 
saline (n = 4/group).  
Cocaine-exposed rats showed higher Pp2cβ promoter 
methylation compared to controls. 
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23 Fragou et al. 
(2013) 
Animal 
(mouse) 
Adulthood 1 Cocaine/her
oin 
Whole brain; 
liver 
Global - Eight-week old male mice with 
either 1) chronic 7-day heroin 
administration (n = 9 vs 9 
controls) or 2) chronic 14-day 
cocaine administration (n = 9 vs 
9 controls). 
No differences in either drug group or tissue vs 
controls. 
24 Chao et al. 
(2014) 
Animal 
(mouse) 
Adulthood 1 Cocaine/her
oin 
Whole brain; 
liver 
Global  - Eight-week old male mice with 
either 1) chronic 7-day heroin 
administration (n= 9 vs 9 
controls) or 2) chronic 14-day 
cocaine administration (n = 9 vs 
9 controls). 
No effects of heroin on methylation or 
hydroxymethylation in brain or liver. 
Hydroxymethylation (but not methylation) was reduced 
in the cocaine group in liver (but not brain tissue). 
           
25 Wilhelm-
Benartzi et 
al. (2012) 
Human Prenatal 1 Alcohol Placenta Global  - Mother-infant pairs (n = 184, 
gender- and maternal-age 
matched infants). 
Mean LINE-1 (but not AluYb8 or global [mean across 
27k]) levels differed by maternal alcohol use during 
pregnancy. 
26 Azzi et al. 
(2014) 
Human Prenatal 1 Alcohol Blood (cord) Candidate  ZAC1 254 mother-newborn pairs 
(subsample from EDEN study; 
mean age = 30). 
Pre-pregnancy and prenatal maternal alcohol intake 
positively correlated with ZAC1 methylation at birth, 
which in turn associated with fetal and postnatal 
weight.  
27 van der 
Knaap et al. 
(2014) 
Human Adolescence 1 Alcohol, 
cannabis 
Blood Candidate  COMT 463 adolescents (mean age =16, 
51% F). 
No association between membrane-bound COMT 
promoter methylation and alcohol or cannabis use; 
significant interaction with COMT Val108/158 Met 
genotype in predicting high-frequent cannabis use.  
28 Ponomarev et 
al. (2012) 
Human Adulthood 1 Alcohol Superior 
frontal cortex 
EWAS  - Postmortem tissue from 17 
alcoholics and 15 matched 
controls (6% females). DNA 
methylation available for a 
subsample of 6 cases and 6 
controls. 
DNA hypomethylation in the LTR region of 3 
retrotransposon gene families: MLT2A1, THE1B, LTR8. 
29 Zhu et al 
.(2012) 
Human Adulthood 1 Alcohol Blood  Global  - Adult alcohol drinkers (n = 
717) vs non-drinkers (n  = 609); 
mean age = 62, 14% females. 
Lower Alu (but not LINE-1) methylation levels in 
drinkers vs non-drinkers. 
30 Zhang  et al. 
(2012) 
Human Adulthood 1 Alcohol  Blood Candidate  OPRM1 125 cases with alcohol 
dependence (mean age = 41, 
35% F) vs 69 controls (mean 
age = 39, 51% F) 
Higher overall OPRM1 methylation in cases vs 
controls. Associations with individual CpG sites (n = 
16) did not survive multiple correction.  
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31 Glahn  et al. 
(2014) 
Human Adulthood 3 Alcohol Blood Candidate  ANP, AVP 99 alcohol-dependent patients 
(mean age = 43) vs 101 controls 
(mean age = 36). All male.  
Significant difference in AVP and ANP methylation 
between cases and controls at baseline (day 1). No 
difference between day 1 and 7 of alcohol withdrawal. 
AVP and ANP methylation (1 CpG each) significantly 
reduced in cases vs controls between day 7 and 14. 
DNA methylation not significantly associated with 
serum levels.  
32 Heberlein et 
al. (2013)  
Human Adulthood 3 Alcohol Blood Candidate  NGF 57 male alcohol-dependent 
patients during withdrawal. 
No significant change in NGF methylation and serum 
levels between day 1 and 7 of alcohol withdrawal. 
Increase in methylation and decrease in serum levels 
between day 7 and 14.  
33 Beach et al 
(2013) 
Human Adulthood 1 Alcohol, 
cannabis 
Blood  Candidate  5-HTT 155 adult females from the 
Iowa adoptees sample                            
(mean age = 41). 
No significant association between 5-HTT methylation 
and substance use. 
34 Nieratschker 
et al. (2014) 
Human Adulthood 2 Alcohol Blood  Candidate  DAT 100 alcoholic patients (mean 
age = 47, 20% F) vs 100 
matched controls. Repeated 
DNA methylation available for 
85 cases (mean age = 47, 18% 
F). 
No difference in DAT methylation between alcoholic 
patients vs controls; no significant change pre- or post-
withdrawal in patients; trend association between 
higher craving and lower methylation.  
35 Zhang et al. 
(2013) 
Human Adulthood 1 Alcohol Blood Candidate  82 genes  285 Alcohol dependent cases 
(mean age = 42, 49% F) vs 249 
controls (mean age = 37, 62% 
F). Replication sample: 49 cases 
(mean age = 42, 47% F) and 32 
controls (mean age 37, 63% F). 
Of 384 sites examined (82 genes), one probe in the 
promoter region of HTR3A was significantly associated 
with European American cases vs controls, after 
multiple correction (trend association in the replication 
sample). No significant differences between cases and 
controls in African Americans.  
36 Zhang et al. 
(2013) 
Human Adulthood 1 Alcohol Liver Candidate  UGT1A1 46 human liver bank samples 
(mean age = 41; 46% F). 
No association between alcohol history and UGT1A1 
methylation (6 CpGs) in liver. However, alcohol 
history influenced the relationship between DNA 
methylation and UGT1A1 protein content and 
enzymatic activity.  
37 Yasar et al. 
(2013) 
Human Adulthood 1 Alcohol  Blood Candidate  LEP 164 alcohol dependent patients 
(mean age = 43; 21% F). 
Lower LEP promoter methylation at baseline 
associated with higher serum leptin levels during 
detoxification (day 7) and stronger alcohol craving in 
alcohol dependent patients.  
38 Hillemacher  
et al. (2015) 
Human Adulthood 1 Alcohol Saliva EWAS  - Community sample of 309 
hazardous drinkers (age = 21-
55, 31%F). Replication sample: 
39 individuals from a 
28 sites were significant after FDR correction, where 
greater methylation levels were associated with poorer 
control over drinking. Increased ALDH1A2 methylation 
also related to faster increase of breath alcohol levels 
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pharmacological intervention 
study (mean age = 44; 30% F). 
DNAm platform: Illumina 27k. 
and increased subjective feeling of intoxication.  
39 Harlaar et al. 
(2014) 
Human Adulthood 1 Alcohol Blood EWAS  - 63 male alcohol-dependent in-
patients (mean age = 44) and 65 
age- and sex-matched healthy 
controls. DNAm platform: 
Illumina 27k. 
1710 sites were differentially methylated in cases vs 
controls with p < 0.005. Top-ranked sites included 
genes previously shown to be related to alcohol 
metabolism (e.g. ADH1A, ALDH3B2, CYP2A13). 
Enriched biological pathways for hypomethylated sites 
included defence response, response to external 
stimulus and immune system process, while 
hypermethylated sites were enriched for mitosis and 
signal transduction. 
40 Philibert et 
al. (2012) 
Human Adulthood 1 Alcohol Blood  EWAS - 165 age-matched females: (i) 40 
abstinent (mean age = 47), (ii) 
47mild, (iii) 50 moderate, and 
(iv) 28 heavy alcohol users. 
DNAm platform: Illumina 
450k. 
No differences pre vs post treatment. ABR differentially 
methylated in heavy/moderate alcohol users vs 
abstinent patients.  
41 Philibert et 
al. (2014) 
Human Adulthood 1 Alcohol Blood  EWAS - 10 alcohol-dependent patients 
(mean age = 45) and their 
discordant siblings as controls 
(mean age = 44). Sex not 
specified. DNAm platform: 
Illumina 450k. 
865 hypomethylated and 716 hypermethylated sites in 
alcohol dependent patients vs controls (SSTR4 most 
hypomethylated; GABRP most hypermethylated). 
Enriched pathways related to metabolic function. 
42 Zhao et al. 
(2013) 
Human Adulthood 2 Alcohol  Blood EWAS  - Two time points within 12-year 
period; cases (n = 10; mean age 
= 40; males) differ from age- 
and sex- matched control (n = 
10) in alcohol consumption at 
time point 2, but not 1. DNAm 
platform: Illumina 27k. 
200 differentially methylated sites in cases between 
time points with a majority of sites increasing in 
methylation over time; sites correlated with alcohol 
consumption over 12-year period related to genes such 
as CKM, PHOX2A, NPDC1, ADCY9.Enriched 
pathways included signal transduction, Notch 
signalling, and p53 network. 
43 Weng et al. 
(2014) 
Human Adulthood 2 Alcohol  Blood  EWAS - 33 subjects with heavy alcohol 
consumption (mean age = 45; 
24% F) and 33 age- and sex-
matched controls; repeated 
measures for 25 cases before 
and after 25-day treatment 
program. DNAm platform: 
Illumina 450k. 
8636 FDR- corrected differentially methylated sites (56 
Bonferroni-corrected). Age, gender and ethnicity not 
included as covariates.  Enriched pathways included 
apoptosis and GTPase signalling. No observed 
differences before vs after treatment. 
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44 Doehring et 
al. (2013) 
Human Adulthood 1 Opiate Blood  Global; 
candidate 
OPRM1 85 methadone-substituted 
former opiate addicts (mean age 
= 35; 30% F) vs matched 
healthy controls. Replication 
sample: 63 opioid-treated pain 
patients (age > 50; 43% F) vs 
matched non-opioid treated 
controls.  
Higher OPRM1 methylation (1 site) and global (LINE-
1) methylation in former opiate addicts vs controls. 
Association with global methylation reproduced in an 
independent sample of opiate-treated pain patients vs 
controls. Within this sample, higher global methylation 
was also positively associated with average daily opioid 
dose and pain scores.  
45 Desplats et 
al. (2014) 
Human Adulthood 1 Meth Frontal cortex Global; 
EWAS  
- HIV-seropositive cases with 
(n=13) and without (n=14) 
methamphetamine-abuse (age- 
and gender-matched). DNAm 
platform: Illumina 450k. 
Increased global methylation in methamphetamine 
HIV+ users compared to HIV+ non-users; EWAS: 
enriched pathways included L-DOPA degradation, 
ERK/MAPK signalling and Dopamine-DARPP32 
feedback in cAMP signalling. 
 
 
 
 
 
